Maple syrup urine disease …

Neurogenetic Disorders

Updated 04.28.2024
Released 12.28.1993
Expires For CME 04.28.2027

Maple syrup urine disease

Authors: Brendan H Lee MD PhD, Lindsay C Burrage MD PhD

See Contributor Disclosures

Editor: AHM M Huq MD PhD

Maple syrup urine disease

In This Article

Quick Link

Introduction

Overview

Maple syrup urine disease is an inborn error of branched-chain ketoacid metabolism that presents classically with metabolic distress in newborns, although milder presentations exist. Branched-chain amino acids (leucine, isoleucine, and valine) and their ketoacids are increased in the blood, and the intake of these amino acids must be controlled. In this article, the authors detail novel approaches to the treatment of maple syrup urine disease, such as the experimental use of phenylbutyrate to prevent the inactivation of the implicated dehydrogenase complex.

Key points

	• Inborn errors of metabolism should be suspected in newborns and infants with unexplained encephalopathies.
	• Soon after birth, maple syrup urine disease classically presents with an encephalopathy accompanied by abnormal movements such as pedaling, ketonuria, and urine with a burnt sugar odor.
	• The metabolic defect is in the branched-chain keto acid dehydrogenase complex, and dietary branched-chain amino acids (leucine, isoleucine, and valine) should be restricted and monitored.
	• Novel therapies investigated include hepatocyte transplantation, drugs to counter oxidative stress, norleucine, and phenylbutyrate to prevent the inactivation of the dehydrogenase complex.

Historical note and terminology

A hereditary encephalopathy with sweet-smelling urine was described in 1954 (56), and shortly thereafter elevations in plasma branched-chain amino acids and their keto acids in the urine were noted (101; 55). A defect in branched-chain alpha-ketoacid dehydrogenase was then identified (22). Dietary therapy was established, and newborn screening programs were implemented (102; 90). The genes encoding the proteins that form the complex were subsequently identified.

Component	Subunit	Mutations in MSUD	MSUD type	Gene	Reference for cloning or identification
Branched-chain alpha-ketoacid decarboxylase	E1-alpha	Yes	IA	BCKDHA	(97)
Branched-chain alpha-ketoacid decarboxylase	E1-beta	Yes	IB	BCKDHB	(62)
Branched-chain dihydrolipoamide acyltransferase	E2	Yes	II	DBT	(23; 24)
Dihydrolipoamide dehydrogenase	E3	Yes	III	DLD	(64)
BCKD kinase		No	N/A	BCKDK	(71)
BCKD phosphatase		Yes	N/A	PPM1K	(65; 66)

Clinical manifestations

Presentation and course

In the classical form of maple syrup urine disease, infants appear well at birth. Symptoms begin after 3 to 5 days and progress rapidly to death within 2 to 4 weeks if branched-chain amino acid restriction is not implemented. Early manifestations include feeding difficulties, irregular respirations, progressive loss of the Moro reflex, and apnea. Severe hypoglycemia and mild hyperammonemia may occur, as may pancreatitis. These infants may develop convulsions, opisthotonos, pedaling movements of the legs, and generalized muscular rigidity with or without intermittent flaccidity. Death may occur following the development of cerebral edema. At autopsy, cortical atrophy is seen on CT or MRI scan. The myelin is usually hypodense, which is thought to be due to failure of myelinization. Localization of edema to the cerebellum and posterior capsule may be pathognomonic (14).

If treatment is initiated within the first week of life, cerebral edema is reversible and the prognosis is good (29). Because respiratory arrest may occur in the neonatal period, care in a tertiary neonatal intensive care unit is recommended. The metabolic derangement and its reversibility in the brain can now be followed using diffusion-weighted imaging and magnetic resonance spectroscopy (41).

Although approximately 80% of patients with maple syrup urine disease present with the classical form and very low residual enzymatic activity (2% or less), most other patients present with intermittent disease and have higher enzymatic activity (5% or more). These patients have a normal psychomotor development but have acute metabolic attacks during catabolic stresses in infancy or childhood (characterized by elevated BCAA, ketonuria, ataxia, and lethargy). Rare patients present with the intermediate form; they have developmental delays but decompensate after the neonatal period. Note that the ex vivo enzymatic activities can be quite different from in vivo measurements of 13C-leucine oxidation (78), illustrating their limited predictive values.

Less severe variants of maple syrup urine disease have symptoms occurring later in childhood following high protein intake or when a catabolic state is produced by fever, surgery, or prolonged fasting. Patients may be averse to protein on diet history and present with developmental and growth delays. Clinical manifestations may occur in early or late childhood and are characterized by intermittent episodes of ataxia, ketoacidosis, and failure to thrive. Intellectual disability and psychomotor delays are sequelae if left undiagnosed and untreated. "Intermittent," "intermediate," and "thiamine-responsive" forms are clinical classifications that are now recognized to overlap with one another and probably reflect the large number of private mutations identified in the genes for branched-chain alpha-ketoacid dehydrogenase and their various effects on dysfunction of this multienzyme complex. The degree of impaired branched-chain alpha-ketoacid dehydrogenase and the amount of environmental stress on the patient determine the rapidity, age of onset, and intensity of symptoms.

Patients from five families have been described with the thiamine responsive form of maple syrup urine disease (19). The pre-requisites for thiamine responsiveness seem to be an intact E1 subunit, at least 1 allele encoding a full-length E2 subunit (albeit containing a missense mutation), and significant intact cell residual activity. Dietary restriction of leucine is still needed in most thiamine-responsive forms.

In type 3 maple syrup urine disease, mutations are found in the E3 subunit. The E3 subunit (dihydrolipoamide dehydrogenase) is shared with the pyruvate dehydrogenase complex and alpha-ketoglutarate dehydrogenase complex. BCKAs and alpha-ketoglutarate are elevated in the urine along with elevated plasma concentrations of lactate, pyruvate, BCAA and alanine. About 20 patients have been reported, and the phenotype is characterized by a progressive encephalopathy with metabolic decompensations beginning in infancy. Renal tubulopathy and cardiomyopathy can occur.

Diagnosis for all forms is best made before irreversible clinical damage is produced through population-based newborn screening (61). In the symptomatic child, the smell of burnt sugar or maple syrup may be manifest in urine, sweat, or ear wax. Cerumen is an excellent concentrator of the lipid-soluble, sweet-smelling derivative of isoleucine (ie, sotolone), and a smell of the otoscope may make a diagnosis. Bedside screening of urine using the dinitrophenylhydrazine (DNPH) reaction is useful though this is not now routine practice. Diagnosis is made by quantitative and qualitative analysis of plasma and urine L-leucine, L-isoleucine, alloisoleucine, and L-valine. Low plasma glutamine can be noted. Gas chromatography of urine will reveal the branched-chain alpha-ketoacids (alpha-ketoisocaproate, alpha-keto-beta methylvaleric, and alpha-ketoisovaleric acids) as well as their hydroxy derivatives when patients are in poor dietary control. Molecular testing or enzymatic analysis of cultured cells can confirm the diagnosis and enable more rational therapeutic decisions, prognosis, and genotyping of other family members (23; 24). Whole-body leucine oxidation of 13C labeled leucine is rarely used except for research protocols (27).

Prognosis and complications

Outcome is not easily predictable (47; 39; 103; 59; 40; 85; 86; 92). However, if the newborn is diagnosed before apnea or secondary central nervous system damage has occurred and is maintained on an appropriate diet of calories, protein, and carbohydrate, prognosis is good (59). Complications include intercurrent infections and over-restricted dietary protein and calories with consequent developmental, growth, and hematological consequences. At the other extreme of complications is recurrent branched-chain alpha-ketoacidosis due to noncompliance or inadequate nutritional control with excessive intake of branched-chain amino acids. If the infant has been apneic with cerebral edema and hypoxemia for a period of time, outcome is guarded and may include irreversible corticospinal and cerebellar dysfunction. Studies have demonstrated an association between both early control of plasma leucine levels and long-term plasma leucine levels and intellectual outcome in patients with maple syrup urine disease (47; 39; 40; 60; 20; 17). A more recent study of 21 French patients with maple syrup urine disease (mean age of 8.7 years) who were treated early and who had mean leucine levels of about 200 uMol/L demonstrated an average full-scale IQ in the normal range, with a subset of patients having higher verbal IQ as compared to performance IQ (12). Interestingly, attention issues were reported by the caregivers of most patients in this cohort (12). In addition, an increased prevalence of neuropsychiatric comorbidities, including mood disorders and anxiety, has been reported in individuals with maple syrup urine disease (60; 01).

Clinical vignette

The first child of a nonconsanguineous couple with a noncontributory family history was born at term without complications after an uneventful pregnancy. On the third day of life and 3 hours after his last breastfeeding, during which he was irritable, the child would not take the breast and was drowsy. He progressively slipped in a comatose state with pedaling movements of the legs and intermittent apnea requiring intubation.

Clinical examination revealed generalized hypertonia, a bulging fontanel, and urine with a burnt sugar smell. DNPH testing of the urine done at the bedside was positive for alpha-ketoacids (cloudy appearance of urine on 1:1 mixture in a clear tube with a DNPH solution consisting of 0.1% 2,4-dinitrophenylhydrazine in 2N HCl). Laboratory investigations revealed a mildly elevated ammonia and severe hypoglycemia. Plasma amino acids showed elevations of leucine, isoleucine, and valine, along with the pathognomonic finding of alloisoleucine.

The infant was managed by hemodialysis and TPN with restriction of leucine but adequate supplementation of valine and isoleucine. The neurologic status and metabolic abnormalities quickly improved; he was switched to enteral feeding and he was weaned from ventilation and dialysis within 24 hours. He was discharged home 5 days later after the parents were taught about his new diet and given instructions on management of minor and major decompensations.

Biological basis

Etiology and pathogenesis

Maple syrup urine disease is caused by defects in the branched-chain alpha-ketoacid dehydrogenase complex proteins. These are nuclear-encoded mitochondrial proteins. Mutations have been identified in four proteins of the complex: E1-alpha and E1-beta subunits composing the dimeric E1 or branched-chain alpha-ketoacid decarboxylase, the branched-chain dihydrolipoamide acyltransferase (E2), and lipoamide oxidoreductase (E3). Several cofactors are involved in the overall reaction, including thiamine pyrophosphate, lipoamide covalently bound to E2, coenzyme A, and flavin and nicotinamide adenine dinucleotides (FAD and NAD). The overall reaction catalyzes the decarboxylation of the branched-chain alpha-ketoacid, acyl-transfer with the thiamine cofactor by E1 to lipoic acid bound to E2, production and release of the branched-chain acyl CoA, reoxidation of lipoic acid by the E3 flavoprotein, and production of NADH and H+ from NAD+ to reduce FAD. The reaction is regulated through inactivation by phosphorylation of two serine residues on E1-alpha through a kinase and activation through their phosphatase PPM1K.

Metabolic role and context of branched-chain keto acid dehydrogenase complex

BCAA = Branched-Chain Amino Acids; BCKA = Branched-Chain Keto Acids; BC acyl-CoAs = Branched-Chain acyl-CoAs; BCATm = mitochondrial branched-chain aminotransferase; BCATc = cytoplasmic branched-chain aminotransferase; KMV = alpha-...

Biallelic variants in PPM1K has been associated with a mild form of maple syrup urine disease (65; 66).

Loading studies in maple syrup urine disease patients revealed that leucine (and alpha-isocaproate, leucine’s ketoacid present in equimolar concentration with leucine) increases were associated with the most severe neurologic symptoms, especially if levels were above 1 mM (90). It was shown as early as 1967 that alpha-isocaproate inhibits the Krebs cycle at concentrations found in maple syrup urine disease patients (25). A plethora of subsequent studies have suggested that the pathophysiology of maple syrup urine disease is complex. Research in the pathophysiology of maple syrup urine disease revolves around:

(1) Inhibition of mitochondrial functions:
	(a) Direct competition of branched-chain alpha-ketoacids for normal substrates of mitochondrial oxidative phosphorylation resulting in depleted pyruvate and ATP; (67; 06)
	(b) AlphaKIC inhibits pyruvate dehydrogenase (PDH) leading to lactate accumulation (especially in the brain) and increased alanine (68; 81; 75; 106)
	(c) AlphaKIC also inhibits alpha-ketoglutarate dehydrogenase (alphaKGDH) leading to accumulation of alphaKG, reduced Krebs cycle flux, and ATP depletion (67; 81; 83)
	(d) Apoptosis induction (45)
	(e) Reactive oxygen species (31; 13; 33; 09; 57; 87), both as a consequence of Krebs cycle inhibition and as mediators of respiratory chain inhibition
	(f) Selenium deficiency and decrease of erythrocyte glutathione activity (08)
	(g) Interference with transamination reactions such as glutamate cycling (104; 107)
	(h) Altered neural progenitor cells in the adult hippocampus (16)
	(i) Cellular dehydration and rebound cerebral edema: with low ATP, Na+/K+ ATPases fail to maintain membrane gradients (93)
(2) Competition of leucine with other large neutral amino acids for transport across the BBB (11; 07; 48), thus, reducing neurotransmitter synthesis, and also reducing cerebral protein synthesis.
(3) Interference with myelin synthesis, which could be secondary to decreased ketone production from BCAA (21; 84)
(4) Decreased alpha-adrenergic and beta-adrenergic receptor binding in synaptosomes (26)
(5) Alterations of intermediate filament phosphorylation (35)
(6) Increased secretion of the neurotrophic cytokine S100B (34)

The mouse model with an iMSUD phenotype provides further evidence for the first two pathophysiological mechanisms and is a useful model for potential therapeutic studies (107). There is also a natural bovine model, but dietary therapy fails to allow survival of this model.

Diagnostic workup

The first pathognomonic sign of maple syrup urine disease may be the sweet-smelling diaper or cerumen at the tip of the otoscope. A bedside diagnosis could be made using the dinitrophenylhydrazine reaction on a few milliliters of urine. On about 1.0 mL of heparinized blood, quantitation of plasma amino acids will lead to a diagnosis. Normal, early-childhood ranges of L-leucine, L-isoleucine, and L-valine concentrations in plasma are 29 to 151 µM, 20 to 96 µM, and 67 to 299 µM, respectively. In classic maple syrup urine disease, plasma leucine concentration will be greater than 400 µM at 48 hours and often may be well above 2000 µM. L-alloisoleucine is a pathognomonic amino acid in maple syrup urine disease and results from the racemization of l-isoleucine during transamination (52). In some chromatographic assays, alloisoleucine co-elutes with isoleucine, thus, preventing its detection and quantification. When the plasma leucine concentration is above 400 µM, its alpha-ketoacid derivative will overcome the renal threshold and appear in urine. Evaluation of urinary organic acids by gas chromatography and mass spectrometry will virtually diagnose maple syrup urine disease and enable immediate dietary intervention. Starvation alone may increase branched-chain amino acids in plasma in normal children but not to concentrations that produce increased urinary branched-chain alpha-ketoacids. Further diagnoses should include enzyme analysis in dermal fibroblasts or transformed lymphoblasts cultured from the patient. These cells or freshly isolated leukocytes can also be used for mutational analysis available in several laboratories (see GeneTests website for most recent approved testing laboratories).

Management

Management of clinically stable infants and children. Management is directed at nutritional therapy to meet the specific needs of the infant in maintaining optimum growth and development. The leucine tolerance as well as valine and isoleucine requirements decrease with age and should be adjusted according to individual patients. Monitoring of amino acids can be performed by the use of dried blood spots at home. Protein and energy requirements also decrease with age, and the diet should be adjusted accordingly. Growth and psychomotor development should be monitored. Essential amino acid deficiency can lead to anemia, acrodermatitis, hair loss, and growth failure amongst other complications and should, thus, be given in sufficient amounts and monitored (74). Micronutrients, fatty acids, and mineral intake should also be adequate (04; 54; 94). Use of LNAA-supplemented formula has been advocated based on clinical data and a mouse model (94). Pharmacological amounts of thiamine (8 to 10 mg/kg per day) should be added but require at least 3 weeks to produce an effect (27). It is important to emphasize the lifelong nature and need for monitoring diet records, growth and development, and biochemical parameters in patients with maple syrup urine disease. Acute and chronic management of maple syrup urine disease should be performed with the help of a metabolic physician, a specialized nutritionist, and, in severe decompensations, an intensivist. Several more detailed works exist on the subject (03; 10; 02; 92; 94; 30) and nutritional management guidelines have been published (32).

Carnitine supplementation. In maple syrup urine disease patients, carnityl adducts of the branched-chain alpha-ketoacids are of minor therapeutic importance in producing an alternative pathway for their excretion. If recurrent ketoacidosis depletes free carnitine, supplementation may be indicated. Also, carnitine has improved the oxidative stress in a mouse model of maple syrup urine disease (50) and may improve oxidative stress in patients with the disorder (57; 58).

Liver transplantation. Liver transplantation has become an increasingly common therapeutic approach in patients with maple syrup urine disease. A case series described outcomes in 54 patients who had liver transplantation in the United States, with 98% patient survival and 96% graft survival (53). Of the 54 patients, the authors described the clinical course of 37 patients who received liver transplants at their own center, and all 37 patients had increased leucine tolerance posttransplantation (53). Even after transplantation, hyperleucinosis with or without encephalopathy has been reported in rare cases in the setting of intercurrent illness, and thus, precautions should be taken in the setting of illness even after liver transplantation (38). Pre- and post-transplantation IQ scores were similar in the majority of 14 patients who were tested (82). However, liver transplantation is associated with improved long-term metabolic stability and reduces the risk for future metabolic decompensations and, thus, likely prevents worsening of cognitive outcome (28).

Management of minor intercurrent illnesses. If the child has a minor intercurrent illness and no obvious neurologic deterioration, he could be followed at home by administration of a high-calorie BCAA-free formula and monitoring of urine with ketone detection sticks or DNPH test if the parents have been appropriately trained to perform the test. A retrospective chart review suggests that the use of leucine-free formula can reduce the plasma leucine level by approximately 50% from the initial level in a 24-hour period in the setting of hyperleucinemia (80).

Management of severe metabolic decompensation.

Prevent catabolism and promote anabolism. Treat infection or precipitating illness and use antiemetics if the patient is nauseous (vomiting can worsen ketoacidosis and complicate enteral feeding). It is of utmost importance to promote anabolism during an acute attack by immediately providing sufficient calories and BCAA-free essential and nonessential amino acids. Depending on the status of the child, one can use orogastric perfusion of BCAA-free formula with excess calories (150 to 170 KCal/kg per day) and adequate protein (3.0 g/kg per day). An intravenous BCAA-free solution has been utilized as an alternative to enteral formula in individuals who cannot tolerate enteral feeds (05). Isoleucine and valine should be supplemented because they will rapidly become limiting for protein synthesis. Alanine, a gluconeogenic amino acid, is a co-substrate for the BCAA aminotransferases and can also be supplemented. Glutamine is used more rapidly in times of stress, and the glutamate-glutamine-GABA cycle is disrupted by leucine; thus, glutamine can also be supplemented (63; 104). Intravenous dextrose with normal saline and 20 meq KCl is recommended initially. Hypoglycemia can be severe in decompensated maple syrup urine disease, but if glucose rises too much with the therapy, insulin can be initiated.

Detoxify blood with hemodialysis. In cases of severe decompensations, eg, with cerebral edema, coma or cardiovascular compromise, extracorporeal removal therapy (ECRT) might become necessary. Several physicians advocate promoting anabolism instead of resorting to ECRT (63; 59). Peritoneal dialysis and exchange transfusions were used early on, but the leucine clearance rate is relatively slow and complications are more frequent than with other techniques. The effectiveness of hemodialysis in maple syrup urine disease has been reported by several groups (76; 77; 96; 44; 79; 73; 69). Continuous venovenous hemodialysis was compared with nutritional support and was shown to be much faster at reducing leucine levels (43; 73). Kinetic modeling can predict the efficiency of continuous hemodialysis (42), and intermittent hemodialysis was shown to be even faster than continuous hemodialysis (69).

Monitor and minimize brain swelling. Monitor signs such as the level of consciousness, hyperreflexia, papilledema, vomiting, headache, hypertension, heart rate deceleration, and abnormal respiratory pattern. Cerebral edema is prevented by rapidly correcting leucine levels, maintaining normal serum sodium levels, correcting acidosis by the use of bicarbonate if necessary, avoiding rapid osmolarity changes, and minimizing stress. If cerebral edema occurs, the use of furosemide, mannitol, and hypertonic saline should be considered with an intensivist.

Experimental therapies. Antioxidants such as vitamin E or C have been suggested to decrease the oxidative stress damage (100; 75). Carbamylglutamate, an analog of N-acetylglutamate that can stimulate the early steps of the urea cycle, has also been shown to have some marginal efficacy at helping to drop ammonia levels during the decompensation of a patient (46). Liver cell transplantation with 3% correction of hepatocytes increases growth and lifespan in mice (89). Similarly, transdermal hepatic injections of human amnion epithelial cells starting in the neonatal period resulted in doubling of BCKDC enzyme activity and reduction in BCAA levels in the serum and brain of mice (88). Subcutaneous transplantation of adipose tissue from wild-type mice into two different mouse models for maple syrup urine disease resulted in decreased BCAA levels compared to untransplanted mice (105). Gene therapy has not yet been reported in experimental models of maple syrup urine disease. Norleucine competes with leucine for brain entry at the blood-brain barrier (95) and has been shown to be effective in treating mice with iMSUD (107). It also appears that norleucine inhibits transamination of leucine to alpha-ketoisocaproate (107; 106). Because phenylbutyrate inhibits BCKDC kinase and increases the complex’s activity in vitro and in vivo, a clinical trial in patients with maple syrup urine disease is underway (15). Interestingly, a rapid reduction in leucine level was observed in the setting of an acute metabolic decompensation in a patient using intravenous sodium phenylacetate/sodium benzoate (51). In addition, a study demonstrated reduction of leucine with oral sodium phenylbutyrate in the setting of acute leucinosis (108). This result suggests that oral sodium phenylbutyrate might be considered for reducing leucine levels in individuals who are not appropriate for extracorporeal removal of leucine or in small centers where this expertise is not available although more controlled studies are likely needed to definitively demonstrate efficacy. Finally, a structurally-based design approach has been used to design a novel inhibitor (S-CPP) of the BCKDC that results in decreased plasma BCAAs after drug delivery (98). Preclinical studies of metformin in the iMSUD mouse model demonstrated a reduction in the levels of leucine and its corresponding ketoacid in skeletal muscle and serum and associated improvements in mitochondrial function (91). Further studies are needed in order to determine whether metformin may be a useful therapeutic option for individuals with maple syrup urine disease.

Gene therapy is also a growing area of investigation in animal models of MSUD. To date, attempts at using liver-directed gene therapy using liver specific promoters in murine models have been suboptimal, with better results achieved using vectors targeting extra-hepatic tissue, such as muscle (36; 70).

References

01: Abi-Warde M, Roda C, Arnoux J, et al. Long-term metabolic follow-up and clinical outcome of 35 patients with maple syrup urine disease. J Inherit Metab Dis 2017;40(6):783-92. PMID 28905140
02: Acosta PB. Nutrition Management of Patients With Inherited Metabolic Diseases. Boston: Jones & Bartlett Publishers, 2009.
03: Albers S, Waisbren SE, Ampola MG, et al. New England Consortium: a model for medical evaluation of expanded newborn screening with tandem mass spectrometry. J Inherit Metab Dis 2001;24(2):303-4. PMID 11405349
04: Aldámiz-Echevarría L, Sanjurjo P, Elorz J, et al. Effect of docosahexaenoic acid administration on plasma lipid profile and metabolic parameters of children with methylmalonic acidaemia. J Inherit Metab Dis 2006;29(1):58-63. PMID 16601869
05: Alili J, Berleur M, Husson M et al. Intravenous administration of a branched-chain amino-acid-free solution in children and adults with acute decompensation of maple syrup urine disease: a prospective multicentre observational study. Orphanet J Rare Dis 2022;17(1):202. PMID 35578286
06: Amaral AU, Leipnitz G, Fernandes CG, Seminotti B, Schuck PF, Wajner M. Alpha-ketoisocaproic acid and leucine provoke mitochondrial bioenergetic dysfunction in rat brain. Brain Res 2010;132475-84. PMID 20153737
07: Araújo P, Wassermann GF, Tallini K, et al. Reduction of large neutral amino acid levels in plasma and brain of hyperleucinemic rats. Neurochem Int 2001;38(6):529-37. PMID 11248401
08: Barschak AG, Sitta A, Deon M, et al. Erythrocyte glutathione peroxidase activity and plasma selenium concentration are reduced in maple syrup urine disease patients during treatment. Int J Dev Neurosci 2007;25(5):335-8. PMID 17574789
09: Barschak AG, Sitta A, Deon M, et al. Oxidative stress in plasma from maple syrup urine disease patients during treatment. Metab Brain Dis 2008;23(1):71-80. PMID 18026828
10: Blau N, Hoffmann G, Leonard J, Clarke J. Physicianʼs Guide to the Treatment and Follow-Up of Metabolic Diseases. Berlin: Springer, 2005.
11: Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci U S A 1999;96(21):12079-84. PMID 10518579
12: Bouchereau J, Leduc-Leballeur J, Pichard S, et al. Neurocognitive profiles in MSUD school-age patients. J Inherit Metab Dis 2017;40(3):377-83. PMID 28324240
13: Bridi R, Braun CA, Zorzi GK, et al. alpha-keto acids accumulating in maple syrup urine disease stimulate lipid peroxidation and reduce antioxidant defences in cerebral cortex from young rats. J Metab Brain Dis 2005;20(2):155-67. PMID 15938133
14: Brismar J, Aqeel A, Brismar G, Coates R, Gascon G, Ozand P. Maple syrup urine disease: findings on CT and MR scans of the brain in 10 infants. AJNR Am J Neuroradiol 1990;11(6):1219-28. PMID 2124065
15: Brunetti-Pierri N, Lanpher B, Erez A, et al. Phenylbutyrate therapy for maple syrup urine disease. Hum Mol Genet 2011;20(4):631-40.** PMID 21098507
16: Calingasan NY, Ho DJ, Wille EJ, et al. Influence of mitochondrial enzyme deficiency on adult neurogenesis in mouse models of neurodegenerative diseases. Neuroscience 2008;153(4):986-96. PMID 18423880
17: Chiong MA, Tan MA, Cordero CP, et al. Plasma amino acid and urine organic acid profiles of Filipino patients with maple syrup urine disease (MSUD) and correlation with their neurologic features. Mol Genet Metab Rep 2016;9:46-53. PMID 27761412
18: Chuang DT, Wynn RM, Shih VE. Maple syrup urine disease (branched-chain ketoaciduria). In: Valle D, Beaudet AL, Vogelstein B, Kinzler K, Antonarakis SE, Ballabio A, editors. The Online Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2008.**
19: Chuang JL, Wynn RM, Moss CC, et al. Structural and biochemical basis for novel mutations in homozygous Israeli maple syrup urine disease patients: a proposed mechanism for the thiamin-responsive phenotype. J Biol Chem 2004;279(17):17792-800. PMID 14742428
20: Couce ML, Ramos F, Bueno MA, et al. Evolution of maple syrup urine disease in patients diagnosed by newborn screening versus late diagnosis. Eur J Paediatr Neurol 2015;19(6):652-9. PMID 26232051
21: Crome L, Dutton G, Ross CF. Maple syrup urine disease. J Pathol Bacteriol 1961;81379-84. PMID 13696537
22: Dancis J, Hutzler J, Levitz M. Metabolism of the white blood cells in maple-syrup-urine disease. Biochim Biophys Acta 1960;43342-3. PMID 13719556
23: Danner DJ, Litwer S, Herring WJ, Elsas LJ. Molecular genetic basis for inherited human disorders of branched-chain alpha-keto acid dehydrogenase complex. Ann N Y Acad Sci 1989a;573369-77. PMID 2699404
24: Danner DJ, Litwer S, Herring WJ, Pruckler J. Construction and nucleotide sequence of a cDNA encoding the full-length preprotein for human branched chain acyltransferase. J Biol Chem 1989b;264(13):7742-6. PMID 2708389
25: Dreyfus PM, Prensky AL. Further observations on the biochemical lesion in maple syrup urine disease. Nature 1967;214(5085):276. PMID 6034241
26: Dwivedi C, James EC, Parmar SS. Effects of abnormal metabolites of maple syrup urine disease on neurotransmitter receptor binding. Biochem Med Metab Biol 1986;35(3):275-8. PMID 3013257
27: Elsas LJ, Ellerine NP, Klein PD. Practical methods to estimate whole body leucine oxidation in maple syrup urine disease. Pediatr Res 1993;33(5):445-51. PMID 8511017
28: Ewing CB, Soltys KA, Strauss KA, et al. Metabolic control and “ideal” outcomes in liver transplantation for maple syrup urine disease. J Pediatr 2021;237:59-64. PMID 34153280
29: Felber SR, Sperl W, Chemelli A, Murr C, Wendel U. Maple syrup urine disease: metabolic decompensation monitored by proton magnetic resonance imaging and spectroscopy. Ann Neurol 1993;33(4):396-401. PMID 8489211
30: Fernandes J, Saudubray JM, Van den Berghe G. Inborn Metabolic Diseases: Diagnosis and Treatment. 5th ed. New York, NY: Springer, 2011.**
31: Fontella FU, Gassen E, Pulrolnik V, et al. Stimulation of lipid peroxidation in vitro in rat brain by the metabolites accumulating in maple syrup urine disease. Metab Brain Dis 2002;17(1):47-54. PMID 11894849
32: Frazier DM, Allgeier C, Homer C, et al. Nutrition management guideline for maple syrup urine disease: an evidence – and consensus-based approach. Mol Genet Metab 2014;112(3):210-7.** PMID 24881969
33: Funchal C, Latini A, Jacques-Silva MC, et al. Morphological alterations and induction of oxidative stress in glial cells caused by the branched-chain alpha-keto acids accumulating in maple syrup urine disease. Neurochem Int 2006;49(7):640-50. PMID 16822590
34: Funchal C, Tramontina F, Quincozes dos Santos A, et al. Effect of the branched-chain alpha-keto acids accumulating in maple syrup urine disease on S100B release from glial cells. J Neurol Sci 2007;260(1-2):87-94. PMID 17499767
35: Funchal C, Zamoner A, Santos AQ dos, Loureiro SO, Wajner M, Pessoa-Pureur R. Alpha-ketoisocaproic acid increases phosphorylation of intermediate filament proteins from rat cerebral cortex by mechanisms involving Ca2+ and cAMP. Neurochem Res 2005;30(9):1139-46. PMID 16292507
36: Greig JA, Jennis M, Dandekar A, et al. Muscle-directed AAV gene therapy rescues the maple syrup urine disease phenotype in a mouse model. Mol Genet Metab 2021;134(1-2):139-46. PMID 34454844
37: Grünewald S, Hinrichs F, Wendel U. Pregnancy in a woman with maple syrup urine disease. J Inherit Metab Dis 1998;21(2):89-94. PMID 9584259
38: Guilder L, Prada CE, Saenz S, et al. Hyperleucinosis during infections in maple syrup urine disease post liver transplantation. Mol Genet Metab Rep 2021;27:100763. PMID 33996492
39: Hilliges C, Awiszus D, Wendel U. Intellectual performance of children with maple syrup urine disease. Eur J Pediatr 1993;152(2):144-7. PMID 8444223
40: Hoffmann B, Helbling C, Schadewaldt P, Wendel U. Impact of longitudinal plasma leucine levels on the intellectual outcome in patients with classic MSUD. Pediatr Res 2006;59(1):17-20. PMID 16326996
41: Jan W, Zimmerman RA, Wang ZJ, Berry GT, Kaplan PB, Kaye EM. MR diffusion imaging and MR spectroscopy of maple syrup urine disease during acute metabolic decompensation. Neuroradiol 2003;45(6):393-9. PMID 12736767
42: Jouvet P, Hubert P, Saudubray JM, Rabier D, Man NK. Kinetic modeling of plasma leucine levels during continuous venovenous extracorporeal removal therapy in neonates with maple syrup urine disease. Pediatr Res 2005;58(2):278-82. PMID 16085796
43: Jouvet P, Jugie M, Rabier D, et al. Combined nutritional support and continuous extracorporeal removal therapy in the severe acute phase of maple syrup urine disease. Intensive Care Med 2001;27(11):1798-806. PMID 11810125
44: Jouvet P, Poggi F, Rabier D, et al. Continuous venovenous haemodiafiltration in the acute phase of neonatal maple syrup urine disease. J Inherit Metab Dis 1997;20(4):463-72. PMID 9266382
45: Jouvet P, Rustin P, Taylor DL, et al. Branched chain amino acids induce apoptosis in neural cells without mitochondrial membrane depolarization or cytochrome c release: implications for neurological impairment associated with maple syrup urine disease. Mol Biol Cell 2000;11(5):1919-32. PMID 10793161
46: Kalkan Ucar S, Coker M, Habif S, et al. The first use of N-carbamylglutamate in a patient with decompensated maple syrup urine disease. Metab Brain Dis 2009;24(3):409-14. PMID 19688253
47: Kaplan P, Mazur A, Field M, et al. Intellectual outcome in children with maple syrup urine disease. J Pediatr 1991;119(1 Pt 1):46-50. PMID 2066858
48: Killian DM, Chikhale PJ. Predominant functional activity of the large, neutral amino acid transporter (LAT1) isoform at the cerebrovasculature. Neurosci Lett 2001;306(1-2):1-4. PMID 11403943
49: Knerr I, Colombo R, Urquhart J, et al. Expanding the genetic and phenotypic spectrum of branched-chain amino acid transferase 2 deficiency. J Inherit Metab Dis 2019;42(5):809-17. PMID 31177572
50: Knerr I, Weinhold N, Vockley J, Gibson KM. Advances and challenges in the treatment of branched-chain amino/keto acid metabolic defects. J Inherit Metab Dis 2012;35(1):29-40. PMID 21290185
51: Kose M, Canda E, Kagnici M, Ucar SK, Coker M. A patient with MSUD: acute management with sodium phenylacetate/sodium benzoate and sodium phenylbutyrate. Case Rep Pediatr 2017;2017:1045031. PMID 28589054
52: Mamer OA, Reimer ML. On the mechanisms of the formation of L-alloisoleucine and the 2-hydroxy-3-methylvaleric acid stereoisomers from L-isoleucine in maple syrup urine disease patients and in normal humans. J Biol Chem 1992;267(31):22141-7. PMID 1429566
53: Mazariegos GV, Morton DH, Sindhi R, et al. Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience. J Pediatr 2012;160(1):116-21.** PMID 21839471
54: Mazer LM, Yi SH, Singh RH. Docosahexaenoic acid status in females of reproductive age with maple syrup urine disease. J Inherit Metab Dis 2010;33(2):121-7. PMID 20217236
55: Menkes JH. Maple syrup disease; isolation and identification of organic acids in the urine. Pediatrics 1959;23(2):348-53. PMID 13633350
56: Menkes JH, Hurst PL, Craig JM. A new syndrome: progressive familial infantile cerebral dysfunction associated with an unusual urinary substance. Pediatrics 1954;14(5):462-7. PMID 13214961
57: Mescka C, Moraes T, Rosa A, et al. In vivo neuroprotective effect of L-carnitine against oxidative stress in maple syrup urine disease. Metab Brain Dis 2011;26(1):21-8. PMID 21380499
58: Mescka CP, Wayhs CA, Vanzin CS, et al. Protein and lipid damage in maple syrup urine disease patients: l-carnitine effect. Int J Dev Neurosci 2013;31(1):21-4. PMID 23137711
59: Morton DH, Strauss KA, Robinson DL, Puffenberger EG, Kelley RI. Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics 2002;109(6):999-1008. PMID 12042535
60: Muelly ER, Moore GJ, Bunce SC, et al. Biochemical correlates of neuropsychiatric illness in maple syrup urine disease. J Clin Invest 2013;123(4):1809-20.** PMID 23478409
61: Naylor EW, Guthrie R. Newborn screening for maple syrup urine disease (branched-chain ketoaciduria). Pediatrics 1978;61(2):262-6. PMID 416414
62: Nobukuni Y, Mitsubuchi H, Endo F, Akaboshi I, Asaka J, Matsuda I. Maple syrup urine disease. Complete primary structure of the E1 beta subunit of human branched chain alpha-ketoacid dehydrogenase complex deduced from the nucleotide sequence and a gene analysis of patients with this disease. J Clin Invest 1990;86(1):242-7. PMID 2365818
63: Nyhan WL, Rice-Kelts M, Klein J, Barshop BA. Treatment of the acute crisis in maple syrup urine disease. Arch Pediatr Adolesc Med 1998;152(6):593-8. PMID 9641714
64: Otulakowski G, Robinson BH. Isolation and sequence determination of cDNA clones for porcine and human lipoamide dehydrogenase. Homology to other disulfide oxidoreductases. J Biol Chem 1987;262(36):17313-8. PMID 3693355
65: Oyarzabal A, Martinez-Pardo M, Merinero B, et al. A novel regulatory defect in the branched-chain α-keto acid dehydrogenase complex due to a mutation in the PPM1K gene causes a mild variant phenotype of maple syrup urine disease. Hum Mutat 2013;34(2):355-62. PMID 23086801
66: Ozcelik F, Arslan S, Caliskan BO, Kardas F, Ozkul Y, Dundar M. PPM1K defects cause mild syrup urine disease: the second case in the literature. Am J Med Genet A 2023;191(5):1360-5. PMID 36706222
67: Patel MS. Inhibition by the branched-chain 2-oxo acids of the 2-oxoglutarate dehydrogenase complex in developing rat and human brain. Biochem J 1974;144(1):91-7. PMID 4462577
68: Patel MS, Auerbach VH, Grover WD, Wilbur DO. Effect of the branched-chain alpha-keto acids on pyruvate metabolism by homogenates of human brain. J Neurochem 1973;20(6):1793-6. PMID 4719322
69: Phan V, Clermont M-J, Merouani A, et al. Duration of extracorporeal therapy in acute maple syrup urine disease: a kinetic model. Pediatr Nephrol 2006;21(5):698-704. PMID 16518628
70: Pontoizeau C, Simon-Sola M, Gaborit C, et al. Neonatal gene therapy achieves sustained rescue of maple syrup urine disease in mice. Nat Commun 2022;13(1):3278. PMID 35672312
71: Popov KM, Zhao Y, Shimomura Y, Kuntz MJ, Harris RA. Branched-chain alpha-ketoacid dehydrogenase kinase: molecular cloning, expression, and sequence similarity with histidine protein kinases. J Biol Chem 1992;267(19):13127-30. PMID 1377677
72: Puffenberger EG. Genetic heritage of the Old Order Mennonites of southeastern Pennsylvania. Am J Med Genet C Semin Med Genet 2003;121C(1):18-31. PMID 12888983
73: Puliyanda DP, Harmon WE, Peterschmitt MJ, Irons M, Somers MJ. Utility of hemodialysis in maple syrup urine disease. Pediatr Nephrol 2002;17(4):239-42. PMID 11956873
74: Puzenat E, Durbise E, Fromentin C, Humbert P, Aubin F. [Iatrogenic acrodermatitis enteropathica-like syndrome in leucinosis]. [Aritcle in French] Ann Dermatol Venereol 2004;131(8-9):801-4. PMID 15505548
75: Ribeiro CA, Sgaravatti AM, Rosa RB, et al. Inhibition of brain energy metabolism by the branched-chain amino acids accumulating in maple syrup urine disease. Neurochem Res 2008;33(1):114-24. PMID 17680360
76: Ring E, Zobel G, Stöckler S. Clearance of toxic metabolites during therapy for inborn errors of metabolism. J Pediatr 1990;117(2 Pt 1):349-50. PMID 2380843
77: Rutledge SL, Havens PL, Haymond MW, McLean RH, Kan JS, Brusilow SW. Neonatal hemodialysis: effective therapy for the encephalopathy of inborn errors of metabolism. J Pediatr 1990;116(1):125-8. PMID 2295952
78: Schadewaldt P, Bodner A, Brösicke H, Hammen HW, Wendel U. Assessment of whole body L-leucine oxidation by noninvasive L-[1-13C]leucine breath tests: a reappraisal in patients with maple syrup urine disease, obligate heterozygotes, and healthy subjects. Pediatr Res 1998;43(5):592-600. PMID 9585004
79: Schaefer F, Straube E, Oh J, Mehls O, Mayatepek E. Dialysis in neonates with inborn errors of metabolism. Nephrol Dial Transplant 1999;14(4):910-8. PMID 10328469
80: Scott AI, Cusmano-Ozog K, Enns G, Cowan TM. Correction of hyperleucinemia in MSUD patients on leucine-free dietary therapy. Mol Genet Metab 2017;122(4):156-9. PMID 29032949
81: Sgaravatti AM, Rosa RB, Schuck PF, et al. Inhibition of brain energy metabolism by the alpha-keto acids accumulating in maple syrup urine disease. Biochim Biophys Acta 2003;1639(3):232-8. PMID 14636955
82: Shellmer DA, DeVito Dabbs A, Dew MA, et al. Cognitive and adaptive functioning after liver transplantation for maple syrup urine disease: a case series. Pediatr Transplant 2011;15(1):58-64. PMID 20946191
83: Shestopalov AI, Kristal BS. Branched chain keto-acids exert biphasic effects on alpha-ketoglutarate-stimulated respiration in intact rat liver mitochondria. Neurochem Res 2007;32(4-5):947-51. PMID 17342410
84: Silberman J, Dancis J, Feigin I. Neuropathological observations in maple syrup urine disease: branched-chain ketoaciduria. Arch Neurol 1961;5351-63. PMID 13912814
85: Simon E, Flaschker N, Schadewaldt P, Langenbeck U, Wendel U. Variant maple syrup urine disease (MSUD)--the entire spectrum. J Inherit Metab Dis 2006;29(6):716-24. PMID 17063375
86: Simon E, Schwarz M, Wendel U. Social outcome in adults with maple syrup urine disease (MSUD). J Inherit Metab Dis 2007;30(2):264. PMID 17310329
87: Sitta A, Ribas GS, Mescka CP, Barschak AG, Wajner M, Vargas CR. Neurological damage in MSUD: the role of oxidative stress. Cell Mol Neurobiol 2014;34(2):157-65. PMID 24220995
88: Skvorak KJ, Dorko K, Marongiu F, et al. Placental stem cell correction of murine intermediate maple syrup urine disease. Hepatology 2013;57(3):1017-23. PMID 23175463
89: Skvorak KJ, Hager EJ, Arning E, et al. Hepatocyte transplantation (HTx) corrects selected neurometabolic abnormalities in murine intermediate maple syrup urine disease (iMSUD). Biochim Biophys Acta 2009;1792(10):1004-10. PMID 19699299
90: Snyderman SE, Norton PM, Roitman E, Holt LE. Maple syrup urine disease, with particular reference to dietotherapy. Pediatrics 1964;34454-72. PMID 14212461
91: Sonnet DS, O’Leary MN, A Gutierrez M, et al. Metformin inhibits branched chain amino acid (BCAA) derived ketoacidosis and promotes metabolic homeostasis in MSUD. Sci Rep 2016;6:28775. PMID 27373929
92: Strauss K, Puffenberger E, Morton D. Maple syrup urine disease. In: Pagon R, Bird T, Dolan C, Stephens K, editors. GeneReviews. Seattle: University of Washington in Seattle, 2009.
93: Strauss KA, Morton DH. Branched-chain ketoacyl dehydrogenase deficiency: maple syrup disease. Curr Treat Options Neurol 2003;5(4):329-41. PMID 12791200
94: Strauss KA, Wardley B, Robinson D, et al. Classical maple syrup urine disease and brain development: principles of management and formula design. Mol Genet Metab 2010;99(4):333-45.** PMID 20061171
95: Tews JK, Repa JJ, Harper AE. Branched-chain and other amino acids in tissues of rats fed leucine-limiting amino acid diets containing norleucine. J Nutrition 1991;121(3):364-78. PMID 2002408
96: Thompson GN, Butt WW, Shann FA, et al. Continuous venovenous hemofiltration in the management of acute decompensation in inborn errors of metabolism. J Pediatr 1991;118(6):879-84. PMID 2040923
97: Tiu AB, Naujokas M, Eisenstein R, Francke U, Barton DE, Hoganson GE. Cloning and chromosome mapping of a cDNA encoding the E1-alpha subunit of branched chain ketoacid dehydrogenase (BCKAD). Am J Hum Genet 1988;43A17.
98: Tso SC, Qi X, Gui WJ, et al. Structure-based design and mechanisms of allosteric inhibitors for mitochondrial branched-chain α-ketoacid dehydrogenase kinase. Proc Natl Acad Sci U S A 2013;110(24):9728-33. PMID 23716694
99: Van Calcar SC, Harding CO, Davidson SR, Barness LA, Wolff JA. Case reports of successful pregnancy in women with maple syrup urine disease and propionic acidemia. Am J Med Genet 1992;44(5):641-6. PMID 1481826
100: Wajner M, Latini A, Wyse AT, Dutra-Filho CS. The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies. J Inherit Metab Dis 2004;27(4):427-48. PMID 15303000
101: Westall R, Dancis J, Miller S. Maple syrup urine disease. Am J Dis Child 1957;94571-2.
102: Westall RG. Dietary treatment of a child with maple syrup urine disease (branched-chain ketoaciduria). Arch Dis Child 1963;38485-91. PMID 14065992
103: Yoshino M, Aoki K, Akeda H, et al. Management of acute metabolic decompensation in maple syrup urine disease: a multi-center study. Pediatr Int 1999;41(2):132-7. PMID 10221014
104: Yudkoff M, Daikhin Y, Nissim I, et al. Brain amino acid requirements and toxicity: the example of leucine. J Nutrition 2005;135(6 Suppl):1531S-8S.
105: Zimmerman HA, Olson KC, Chen G, Lynch CJ. Adipose transplant for inborn errors of branched chain amino acid metabolism in mice. Mol Genet Metab 2013;109(4):345-53. PMID 23800641
106: Zinnanti WJ, Lazovic J. Interrupting the mechanisms of brain injury in a model of maple syrup urine disease encephalopathy. J Inherit Metab Dis 2012;35(1):71-9. PMID 21541722
107: Zinnanti WJ, Lazovic J, Griffin K, et al. Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease. Brain 2009;132(Pt 4):903-18. PMID 19293241
108: Zubarioglu T, Dede E, Cigdem H, et al. Impact of sodium phenylbutyrate treatment in acute management of maple syrup urine disease attacks: a single-center experience. J Pediatr Endocrinol Metab 2020;34(1):121-6. PMID 33180043

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Brendan H Lee MD PhD

Dr. Lee of Baylor College of Medicine received honorariums from Biomarin for data safety board membership.
See Profile
Lindsay C Burrage MD PhD

Dr. Burrage of Baylor College of Medicine has no relevant financial relationships to disclose.
See Profile

Editor

AHM M Huq MD PhD

Dr. Huq of Wayne State University has no relevant financial relationships to disclose.
See Profile

Former Authors

Louis J Elsas II MD
Raphael Schiffmann MD
Martha D Carlson MD PhD
Philippe Campeau MD

Patient Profile

Age range of presentation: 0 month to 18 years
Sex preponderance: male=female
Heredity: heredity typical

heredity may be a factor

autosomal recessive
Population groups selectively affected: Mennonites
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Maple-syrup-urine disease: E71.0
ICD-11: Maple syrup urine disease: 5C50.D0
OMIM: Maple syrup urine disease: #248600

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Maple syrup urine disease

Associated Disorders

Inherited metabolic disorder
Organic aciduria
Disorder of amino acid metabolism

Differential Diagnosis

propionic and methylmalonic acidemia
branched-chain amino acid transferase 2 (BCAT2) deficiency
prolonged fasting
ketosis

Also Relevant

Alpha-ketoglutarate dehydrogenase deficiency
Hyperammonemia not caused by liver failure
Nondominant hereditary ataxias
Screening of newborns for neurogenetic abnormalities

Clinical Categories

Neurogenetic Disorders

Maple syrup urine disease …

Maple syrup urine disease

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Carnitine palmitoyltransferase II deficiency

Pyruvate carboxylase deficiency

Pelizaeus-Merzbacher disease

Vanishing white matter disease

Wilson disease

Aromatic L-amino acid decarboxylase deficiency

White matter abnormalities in the brain

Hypermethioninemia

Maple syrup urine disease

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Carnitine palmitoyltransferase II deficiency

Pyruvate carboxylase deficiency

Pelizaeus-Merzbacher disease

Vanishing white matter disease

Wilson disease

Aromatic L-amino acid decarboxylase deficiency

White matter abnormalities in the brain

Hypermethioninemia

This is an article preview.
Start a Free Account
to access the full version.